Cabometyx, Cometriq (cabozantinib) is a small molecule pharmaceutical. Cabozantinib was first approved as Cabometyx on 2012-11-29. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret. Cometriq's patents are valid until 2033-07-09 (FDA).
|Trade Name||Cabometyx, Cometriq|
|Indication||hepatocellular carcinoma, renal cell carcinoma, thyroid neoplasms|
|Drug Class||Tyrosine kinase inhibitors|